Stock Ratings / Health Care / LFMD / financials

AIRS (33) NAKA (18) ALPS (50) EUDA (35) ⌘ Pro Terminal →

LifeMD Inc. (LFMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.29 -1.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.28

LifeMD Inc. (LFMD) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $111.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, LifeMD Inc. (NASDAQ: LFMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.29 (-1.29% 1D, market cap $111.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LFMD ranks #779 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFMD compare to AIRS and NAKA in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), LFMD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 85.7%, and ROIC of -26.2%. By comparison, AIRS (AirSculpt Technologies Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -7.0%, cap $120.4M) and NAKA (Nakamoto Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -31.6%, cap $126.2M). Among the 5-stock peer group, LFMD leads on earnings multiple (N/A) while AIRS leads on capital efficiency (-7.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFMD?

▼

Per LFMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000948320), LifeMD Inc. generated $194.1M in revenue (+25.3% YoY), -$11.2M in net income, and $6.4M in free cash flow against $70.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.28 (-0.42%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-11.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFMD)Realized 20D OHLCV Swing Band: ±11.6%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY LFMD SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+9/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 45% Net Buy • Disciplined Float (-0.40% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 3.3% FCF Margin ($6.4M FCF) & 85.7% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.55-11.8% Next Q

Q2 (-2Q)

Grade E$2.25-7.6% Next Q

Q3 (-1Q)

Grade E$2.08+10.1% Next Q

Current

Grade E$2.29-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LFMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LFMD currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.80) and Max Pain ($2.40) forces dealer call-delta covering toward $6.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LFMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LFMD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$6.4M (3.3% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $152.5M

FY24

Rev $154.8M

FY25

Rev $194.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$194.1M	85.7%	-4%	-$11.2M	$6.4M	-26.2%
FY 2024	$154.8M	86.2%	-13.2%	$24.5M	$16.0M	-45%
FY 2023	$152.5M	85.7%	-9.5%	$17.8M	$8.8M	-26.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LFMD)

✓Walkthrough of LFMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.01%🛡️ HOLDING TREND SUPPORT

2026-11-02O $2.23H $2.32L $2.23C $2.29VOL 739.7K

RES: $2.85SUP: $1.98SMA50: $2.80SMA200: $3.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFMD Butterfly Map → + Track LFMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LFMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFMD)

Health Care Rank #779 of 1016 ⚔️ AIRS vs LFMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFMD vs. AIRS, NAKA, ALPS, EUDA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LifeMD Inc. (LFMD) ranks #779 by composite RQD confidence (32/100, grade E) and #645 by equity capitalization ($111.8M). Within this direct 5-issuer industry benchmark cohort, LFMD leads on earnings valuation at N/A trailing P/E, while AIRS leads on capital efficiency and profitability with -7.0% ROIC and — gross margin. ALPS currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with LFMD at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFMD ACTIVE LifeMD Inc.	E	32/100	—	85.7%	-26.2%	-1.29%	$111.8M	Benchmark Subject
AIRS AirSculpt Technologies Inc.	E	33/100	—	—	-7.0%	+3.59%	$120.4M	/airs-vs-lfmd →
NAKA Nakamoto Inc.	E	18/100	—	—	-31.6%	-14.83%	$126.2M	/naka-vs-lfmd →
ALPS ALPS Group Inc Ordinary Share	D	50/100	—	—	—	+0.03%	$54.1M	/alps-vs-lfmd →
EUDA EUDA Health Holdings Limited	D-	35/100	—	43.9%	-35.0%	+14.19%	$46.4M	/euda-vs-lfmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000948320

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LifeMD Inc. (LFMD) reported GAAP revenue of $194.1M (+25.3% vs. FY2024 revenue of $154.8M , and +27.2% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of $8.3M, and free cash flow of $6.4M (-60.1% YoY). On the balance sheet, LFMD closed FY2025 with $70.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$194.1M	-$11.2M	$8.3M	$6.4M	$70.4M	—
FY2024 (FY)	2024-12-31	$154.8M	$24.5M	$17.5M	$16.0M	$76.1M	—
FY2023 (FY)	2023-12-31	$152.5M	$17.8M	$8.8M	$8.8M	—	—

3. LFMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LFMD compare to AIRS and NAKA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LFMD?

Where is LFMD trading relative to its 50-day, 200-day, and 52-week technical levels?

LFMD last traded at $2.29 (-1.29% on volume of 599,137 shares), positioning the stock -18.21% below its 50-day simple moving average ($2.80) and -37.43% below its 200-day simple moving average ($3.66). Across its 52-week range of $2.06 to $6.03, LFMD sits at the 5.8% percentile with a 14-day RSI of 40.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($2.02 to $2.56).

LFMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is LifeMD Inc. (LFMD)?

In FY 2025 (10-K), LFMD converted $194.1M of revenue into a 85.7% gross margin, 0% operating margin, and $6.4M in free cash flow (3.3% FCF margin).

Direct Sub-Reports: LFMD RQD Cockpit LFMD 12M Forecast LFMD Earnings & Move LFMD Dividends & DRIP LFMD Insiders & 13F LFMD Whale Options LFMD Profit Sankey LFMD News & Why

Sector Peer Dials

Compare →

AIRS E

AirSculpt Technologies Inc.

ALPS Group Inc Ordinary Share

50 /100

EUDA D-

EUDA Health Holdings Limited

35 /100

BMGL D+

Basel Medical Group Ltd

LFMD Core Snapshot

Market Cap $111.8M

Trailing / Fwd P/E — / —

Gross Profit Margin 85.7%

Return on Capital (ROIC) -26.2%

Free Cash Flow Yield 5.73%

12M Base Price Target $2.02

FREE TRADER TOOLS

Own LFMD Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With LFMD → 🏆 Trade LFMD in $100K Prop Arena →

LFMD Wire

Why It Moved →

Peer / Ecosystem Wire Yahoo Finance • 13h ago

LifeMD to Report Third Quarter 2026 Financial Results on November 9

Direct Company Event GuruFocus • 16h ago

FEDERATED HERMES, INC. Adds LifeMD Inc (LFMD) -- Shares Look 57% Undervalued on GF Value

Direct Company Event Yahoo Finance UK • 19h ago

LifeMD, Inc. (LFMD) Seasonal returns chart

Peer / Ecosystem Wire Yahoo Finance • 1d ago

MDxHealth (MDXH) Stock Sees Fair Value Cut After Revenue Miss And Guidance Suspension

Peer / Ecosystem Wire Yahoo • 7d ago

What Medifast (MED) Said on Its Q3 Earnings Call

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LFMD — LifeMD Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LifeMD Inc. carries an RQD Score of 32 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars, each scored out of 20, are: Fundamental Cash Engine 8 (ROIC -26.2%; FCF yield 5.73%); Whale 13F Flow 3 (institutional accumulation and options positioning); Insider Conviction 9 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 7 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 5 (Altman Z 0.2; Piotroski F 6/9; Debt/Equity 0.5). For a prospective investor, the weakest pillar relative to its ceiling is whale/institutional flow, while the forensic balance sheet pillar signals elevated distress risk as reflected in the low Altman Z. The most constructive element is the positive FCF yield of 5.73%, which is a cash-generation datapoint but is offset by negative ROIC. The rating frames the stock as a forensic-risk name; any valuation tradeoff (for example, a low absolute share price against a 52-week range of $2.06 - $6.03) should be weighed against the balance-sheet and returns signals rather than the price alone. This is educational analysis, not personalized advice.

Recent Catalysts & News Wire Analysis

Earnings timing (YELLOW): LifeMD is scheduled to report third-quarter 2026 financial results on November 9, per the news wire.
Institutional activity (YELLOW): A report notes that Federated Hermes, Inc. added LifeMD shares, citing a GuruFocus fair-value estimate that the shares look 57% undervalued; this reflects a third-party valuation view, not a confirmed fundamental figure.
Risk watch (RED): A Yahoo Finance item flagged a fair value cut for MDxHealth (MDXH) after a revenue miss and guidance suspension. This item concerns a different issuer and is tagged as relevant to LFMD only through the wire's related-symbol field; it is a sector-sentiment signal rather than a direct LifeMD event.
Seasonal chart (YELLOW): A Yahoo Finance UK seasonal returns chart was published; no quantitative content is provided in the source.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

What are LifeMD's specific products, customer base, and revenue mix behind the reported $194.1M in FY 2025 revenue?
What are the period-end cash and debt balances, which are N/A or not provided in most reported periods?
What drove the swing from FY 2024 net income of $24.5M to FY 2025 net income of $-11.2M?
What is the actual EPS and what are the P/E and EV/EBITDA multiples, given their absence from the source?
What do the insider, 13F, and Congressional flows underlying the RQD pillar scores actually consist of?

LFMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LifeMD Inc. (LFMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFMD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 13h ago

LifeMD to Report Third Quarter 2026 Financial Results on November 9

Yahoo Finance report covering LifeMD Inc. (LFMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 16h ago

FEDERATED HERMES, INC. Adds LifeMD Inc (LFMD) -- Shares Look 57% Undervalued on GF Value

GuruFocus report covering LifeMD Inc. (LFMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 19h ago

LifeMD, Inc. (LFMD) Seasonal returns chart

Yahoo Finance UK report covering LifeMD Inc. (LFMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

MDxHealth (MDXH) Stock Sees Fair Value Cut After Revenue Miss And Guidance Suspension

Yahoo Finance report covering LifeMD Inc. (LFMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 7d ago

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was withi

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 41d ago

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to ho

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 43d ago

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

LifeMD, Inc. (NASDAQ:LFMD) announced an exclusive healthcare collaboration on September 15 that initially makes virtual-health membership benefits available to approximately 29 million eligible AT&T wireless and fiber cu

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 47d ago

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFMD Bull vs. Bear Conversation Board — What's Your Call at $2.29?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFMD 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.04 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LFMD (E • RQD 32/100) a Buy at $2.32?

Welcome to the LFMD (LifeMD Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.95 (-15.9%)

Spot @ $2.32

Pump the brakes on LFMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LFMD, but look at what you are paying: current EV/EBITDA multiples with 85.7% gross margins. Unless LifeMD Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.88 (+24.1%)

Spot @ $2.32

LFMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LFMD, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $2.32 (52-wk range $2.06 - $6.03), any beat on forward guidance forces shorts and underweight funds to chase.